Traverse City Record-Eagle

Opinion

November 24, 2012

Another View: Balance needed in oversight

So far, 32 people have died of fungal meningitis after they were injected with tainted steroids made at a compounding pharmacy here in Massachusetts. Another 438 people in 18 states have fallen ill.

What those patients didn't know is that the pharmacy that made the steroids and others like it have been largely exempted from Food and Drug Administration oversight.

More FDA oversight in the specialty businesses is needed, but it should be done in a way that does not bring onerous regulation to the many small compounding pharmacies that provide a valuable service for patients and doctors.

Most of the compounding pharmacies are small operations that custom-mix drugs, such as specific compounds to treat children or seniors who can't easily swallow pills.

The small, specialized industry doesn't come under the same regulation as large drug makers that must ensure they're operating sterile facilities in a safe manner.

But some compounding pharmacies have grown into mega-drug manufacturers that are pushing the legal limits.

An FDA official warned in 2003 that some large compounders were using "creative marketing" to sell drugs they claimed were superior, without any evidence of support. Still others were manufacturing drugs they claimed were unique, when they were in fact simply cheaper versions of existing drugs.

Regulation of compounding pharmacies has been left to the states, with some assuming that role well, while others are unprepared to provide real oversight. . . .

Compounding pharmacies provide a vital service in the medical field, producing speciality medicines in quantities too small to attract the interest of big pharmaceutical manufacturers.

In Washington, committees in both the House and Senate are holding hearings on the meningitis outbreak that has been linked to the pharmacy. Legislators are vowing to crack down with new federal regulations on the compounding industry. But industry officials are insisting that regulation of their operations should remain with the states.

Congress will need to find ways to rein in compounding pharmacies that are operating in an unsafe manner. But they and the FDA must also be careful not to put needless and costly regulations on legitimate smaller operations. . . .

The Eagle-Tribune North Andover, Mass.

1
Text Only

Opinion Poll
AP Video
Raw: Royal Couple Visits Australia Mountains Raw: Pro-Russian Militants Killed on Base Captain of Sunken South Korean Ferry Apologizes Boston Bombing Survivors One Year Later Sister of Slain MIT Officer Reflects on Bombing Raw: Blast at Tennessee Ammunition Plant Kills 1 Hoax Bomb Raises Anxiety in Boston Egypt Clamps Down on Mosques to Control Message After Fukushima, Japan Eyes Solar Power New York Auto Show Highlights Latest in Car Tech Ex-California City Leader Gets 12 Year Sentence Disbanding Muslim Surveillance Draws Praise Hundreds Missing After South Korean Ferry Sinks Passengers Abuzz After Plane Hits Swarm of Bees Town, Victims Remember Texas Blast At Boston Marathon, a Chance to Finally Finish Are School Dress Codes Too Strict?